{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:17:32Z","timestamp":1788585452860,"version":"build-2803163510"},"reference-count":20,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.5551\/jat.66214","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:12:03Z","timestamp":1778191923000},"page":"1148-1156","source":"Crossref","is-referenced-by-count":1,"title":["A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants"],"prefix":"10.5551","volume":"33","author":[{"given":"Henry","family":"Fok","sequence":"first","affiliation":[{"name":"Silence Therapeutics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rider","sequence":"additional","affiliation":[{"name":"Silence Therapeutics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Owada","sequence":"additional","affiliation":[{"name":"Medical Corporation Heishinkai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Rambaran","sequence":"additional","affiliation":[{"name":"Silence Therapeutics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, Tsutsumi A, Nakamura Y, Igarashi M. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol, 1995; 141: 815-821","DOI":"10.1093\/oxfordjournals.aje.a117516"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tada H, Yamagami K, Nishikawa T, Yoshida T, Teramoto R, Sakata K, Takamura M, Kawashiri MA. Lipoprotein (a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients. Intern Med, 2020; 59: 1705-1710","DOI":"10.2169\/internalmedicine.4503-20"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J, 2022; 43: 3925-3946","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"#cr-split#-5.1","doi-asserted-by":"crossref","unstructured":"5) Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol, 2024","DOI":"10.1016\/j.jacl.2024.03.001"},{"key":"#cr-split#-5.2","unstructured":"5) Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein"},{"key":"#cr-split#-5.3","doi-asserted-by":"crossref","unstructured":"(a) in clinical practice. J Clin Lipidol, 2024; 18: e308-e319","DOI":"10.1016\/j.jacl.2024.03.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA, 2009; 301: 2331-2339","DOI":"10.1001\/jama.2009.801"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol, 2021: 465-474","DOI":"10.1161\/ATVBAHA.120.315291"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, Stitziel NO, Nomura A, Zekavat SM, Bick AG, Gupta N, Asselta R, Duga S, Merlini PA, Correa A, Kessler T, Wilson JG, Bown MJ, Hall AS, Braund PS, Samani NJ, Schunkert H, Marrugat J, Elosua R, McPherson R, Farrall M, Watkins H, Willer C, Abecasis GR, Felix JF, Vasan RS, Lander E, Rader DJ, Danesh J, Ardissino D, Gabriel S, Saleheen D, Kathiresan S; CHARGE\u2013Heart Failure Consortium; CARDIoGRAM Exome Consortium. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol, 2016; 68: 2761-2772","DOI":"10.1016\/j.jacc.2016.10.033"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C, Campion GV. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA, 2022; 327: 1679-1687","DOI":"10.1001\/jama.2022.5050"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, Szarek M, Stroes ESG, Troquay R, Dorresteijn JAN, Fok H, Rider DA, Romano S, Wolski K, Rambaran C. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA, 2024; 332: 1992-2002","DOI":"10.1001\/jama.2024.21957"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nissen SE, Wolski K, Watts GF, Koren MJ, Fok H, Nicholls SJ, Rider DA, Cho L, Romano S, Melgaard C, Rambaran C. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA, 2024; 331: 1534-1543","DOI":"10.1001\/jama.2024.4504"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Arafa A, Kato Y, Kokubo Y, Khairan P, Matsumoto C, M Nakao Y, Kataoka Y, Harada-Shiba M. Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study. J Atheroscler Thromb, 2025; 32: 1139-1149","DOI":"10.5551\/jat.65437"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Jing X, Arya V, Reynolds KS, Rogers H. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs. Drug Metab Dispos, 2023; 51: 193-198","DOI":"10.1124\/dmd.122.001107"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Sohn W, Winkle P, Neutel J, Wu Y, Jabari F, Terrio C, Varrieur T, Wang J, Hellawell J. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. Clin Ther, 2022; 44: 1237-1247","DOI":"10.1016\/j.clinthera.2022.07.008"},{"key":"15","unstructured":"15) Application number 215842. Division of Cardiology and Nephrology, Center for Drug Evaluation and Research, US Food and Drug Administration 2023"},{"key":"16","unstructured":"16) Application Number 219447. Division of Diabetes, Lipid Disorders, and Obesity; Center for Drug Evaluation and Research; US Food and Drug Administration 2025"},{"key":"17","unstructured":"17) Application Number: 214012. Office of Clinical Pharmacology Review; Center for Drug Evaluation and Research; US Food and Drug Administration 2019"},{"key":"18","unstructured":"18) Application number: 215515. Office of Clinical Pharmacology Review; Center for Drug Evaluation and Research US Food and Drug Administration 2022"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_66214\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:52:38Z","timestamp":1788583958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_66214\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66214","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"66214"}}